Hemodialysis Patients with Cardiovascular Disease Reveal Increased Tissue Na\(^+\) Deposition

Anna-Carolina Friedrich\(^a\)  Peter Linz\(^a, b\)  Armin M. Nagel\(^b, c\)
Daniela Rosenhauer\(^a\)  Stephan Horn\(^d\)  Mario Schiffer\(^a\)  Michael Uder\(^b\)
Christoph Kopp\(^a\)  Anke Dahlmann\(^a\)

\(^a\)Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; \(^b\)Institute of Radiology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; \(^c\)Division of Medical Physics in Radiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany; \(^d\)Kuratorium für Heimdialyse, Erlangen, Germany

Keywords
Hemodialysis · Cardiovascular disease · Tissue Na\(^+\) · \(^{23}\)Na-magnetic resonance imaging

Abstract

**Background:** The relationship between Na\(^+\) balance and cardiovascular disease (CVD) in hemodialysis (HD) patients is not yet fully understood. We hypothesized that HD patients co-diagnosed with CVD show increased tissue Na\(^+\) accumulation compared to HD patients without CVD. **Methods:** In our observational study, 52 HD patients were divided into a group with (23 subjects) or without (29 subjects) a positive history of cardiovascular events. We used \(^{23}\)Na-magnetic resonance imaging (\(^{23}\)Na-MRI) at 3.0 Tesla to quantify Na\(^+\) content in skin and muscle of both groups directly before and after HD. Additionally, total body fluid distribution was determined by bioimpedance spectroscopy (BIS) and laboratory parameters were assessed. **Results:** Compared to HD patients without CVD, \(^{23}\)Na-MRI detected an increased Na\(^+\) content in skin (21.7 ± 7.3 vs. 30.2 ± 9.8 arbitrary units (a.u.), \(p < 0.01\)) and muscle tissue (21.5 ± 3.6 vs. 24.7 ± 6.0 a.u., \(p < 0.05\)) in patients with previous CVD events. Simultaneously measured fluid amount by BIS, including excess extracellular water (1.8 ± 1.7 vs. 2.2 ± 1.7 L, \(p = 0.44\)), was not significantly different between both groups. Tissue Na\(^+\) accumulation in HD-CVD patients was paralleled by a higher plasma concentration of the inflammation marker interleukin-6 (5.1, IQR 5.8 vs. 8.5, IQR 7.9 pg/mL, \(p < 0.05\)). **Conclusion:** In our cohort, HD patients with CVD showed higher tissue Na\(^+\) content than HD patients without CVD, while no difference in body water distribution could be detected between both groups. Our findings provide evidence that the history of a cardiovascular event is associated with disturbances in tissue Na\(^+\) content in HD patients.

Introduction

The relationship between salt intake, Na\(^+\) balance, and cardiovascular disease (CVD) is imperfectly understood [1–3]. Both high and low urinary Na\(^+\) levels have been...
associated with increased cardiovascular mortality [4]. In patients with chronic kidney disease (CKD), disturbed Na⁺ homeostasis has been associated with hypertension as well as CVD [5]. Specifically, a dysfunctional regulation of tissue bound Na⁺ appears to play a significant role in developing salt-sensitive hypertension [6–8]. Tissue Na⁺ deposition has been discovered as a relevant mechanism of Na⁺-homeostasis alongside extracellular fluid expansion [6]. Patients with end-stage CKD depend on hemodialysis (HD) treatment for Na⁺ excretion, thereby regulating blood pressure and reducing CVD risk [9, 10]. However, recent studies suggest that total body Na⁺ content behaves independently of Na⁺ intake and does not correlate with water retention, weight gain, or renal excretion [11, 12]. A quantifiable marker for Na⁺ deposition in tissue therefore would be desirable for a more precise estimation of total body Na⁺ content. Implementation of ²³Na-magnetic resonance imaging (²³Na-MRI) allows quantifying tissue Na⁺ content in humans noninvasively [13–18]. In several studies, it could be shown that HD patients are tissue Na⁺ overloaded, particularly those co-diagnosed with type 2 diabetes mellitus [15, 19–22]. Furthermore, skin Na⁺ content in patients with CKD correlates with left ventricular mass [23], a surrogate factor of CVD. We hypothesized that an association between tissue Na⁺ deposition and CVD exists in HD patients and that tissue Na⁺ may represent a novel risk marker.

Methods

As tissue Na⁺ is age-dependent [14] and cardiovascular events most commonly occur in elderly patients, we conducted an observational study in a cohort of 52 HD patients over the age of 50 years. A further inclusion criterion was HD vintage time of at least 6 months. Exclusion criteria were active malignancy, severe heart failure (NYHA IV), severe liver disease (CHLH C), acute infectious situation, and recent major surgical procedures (<3 months). Additionally, patients with pacemakers, implants, or other MRI contraindications were excluded. Scans were conducted at the Institute of Radiology, University Hospital of Erlangen.

Study Protocol

Fifty-two HD patients ≥50 years of age were divided into 2 groups in regard to preexisting cardiovascular events as defined by the American Heart Association [24]. For this purpose, we surveyed medical history, including available echocardiography, duplex sonography of arteries or electrocardiogram, for events of coronary artery disease (myocardial infarction or previous bypass surgery/stent implantation), heart failure (NYHA III), hypertensive heart disease, persisting arrhythmia, history of stroke or TIA, carotid artery stenosis >70%, peripheral arterial disease (stage III/IV), deep venous thrombosis, or pulmonary embolism. All HD patients with such an event in their medical history were placed in the "cardiovascular group" (HD-CVD, \( n = 23 \)), detailed information is shown in online suppl. Table 1; for all online suppl. material, see www.karger.com/doi/10.1159/000520821). The remaining subjects served as controls (HD-Controls, \( n = 29 \)). Each patient’s dialysis regimen including interdialytic weight gain, residual diuresis, prescribed dialysate composition, and applied ultrafiltration volume were documented. Preceding pre-dialytic ²³Na-MRI scans, medical exams determining a subject’s height, weight, blood pressure, and body fluids were performed, followed by a venous blood sample. Blood pressure was measured after 5 minutes of rest in a seated position using an automated oscillometric device (Dinamap; Critikon, Carlsbad, CA, USA) prior to HD. In patients without fistula, blood pressure was analyzed on both upper arms and the arm with higher pressure was chosen. Three consecutive measurements were averaged. Venous blood samples were taken before HD treatment, centrifuged, and stored at -80°C. Plasma determination of interleukin-6 (IL-6) and N-terminal-pro-hormone of brain natriuretic peptide (NT-proBNP) concentration were performed by electro-chemiluminescence immunoassay, high-sensitive troponin I (hs-TnI) by chemiluminescence assay and high-sensitive C-reactive protein by nephelometric assay. Serum vascular endothelia growth factor-C concentration was determined by enzyme-linked immune-sorbent assays. ²³Na-MRI scans were conducted pre-dialysis and assessed for tissue Na⁺ content. To analyze tissue Na⁺ mobilization by HD treatment, we additionally performed ²³Na-MRI scans after HD treatment in 27 HD-control and 23 HD-CVD patients. Na⁺ mobilization (ΔNa⁺) was calculated by subtracting tissue Na⁺ amount after HD from the pre-dialysis tissue Na⁺ content.

²³Na-MRI Assessment

Na⁺ tissue content of the skin and the M. triceps surae were measured in a conventional 3 Tesla ¹H-MRI-scanner (Magnetom Verio or Magnetom Skyra; Siemens Healthineers, Erlangen, Germany), using a volume coil (Stark-Contrast, Erlangen, Germany) positioned around the left calf, centered at the area of the largest circumference. Blood vessels were excluded from the regions of interest (ROI). ²³Na-MRI images were acquired using a 2D gradient-echo sequence (total acquisition time TA = 13.7 min, echo time TE = 2.07 ms, repetition time TR = 100 ms, flip angle FA = 90, 128 averages, resolution: 3 × 3 × 30 mm³). Images were analyzed using validated software (ImageJ, University of Wisconsin, Madison, WI, USA). Due to the higher resolution, ROI are first outlined in the ¹H-images and subsequently projected onto the ²³Na image. Four tubes containing NaCl-solutions (10, 20, 30, and 40 mmol/L Na⁺) in the coil base were used to calibrate signal intensities to Na⁺ concentrations.

The low in-plane resolution of ²³Na-MRI imaging results in partial volume effects and thus in an underestimation of the Na⁺ skin content, since the skin thickness is approximately 1 mm. In addition, the Na⁺ concentration of subcutaneous fat tissue influences the measured skin Na⁺, and the fast decay of the ²³Na-MRI signal can result in an underestimation of tissue Na⁺ amount. To account for these limitations, we labeled the tissue Na⁺ concentration obtained by the calibration as arbitrary units (a.u.).

Bioimpedance Spectroscopy

We used multifrequency bioimpedance spectroscopy (BIS) to noninvasively assess the patient’s fluid status (Body composition...
monitor (BCM); Fresenius Medical Care, Bad Homburg, Germany). This technique uses bioelectrical impedance to differentiate between extracellular water and intracellular water. Additionally, it calculates the overhydration (OH), i.e., the excess extracellular fluid compared to healthy individuals of the same age. As we implemented this technique later on in the trial, we only have this information for 25 HD-controls and 22 HD-CVD subjects.

Statistics
All data were analyzed by IBM SPSS statistics (version 24). The Kolmogorov-Smirnov test was used to assess the distribution of our data. All normal distributed data were subsequently analyzed using the independent Student’s t test, data with a skewed distribution were analyzed using the Mann-Whitney U test. Results were expressed as mean ± SD for normally distributed data and as median and IQR for the data lacking a normal distribution. A p value <0.05 was considered significant and two-sided tests of hypotheses were used throughout. Pearson’s correlation was used to compute the correlation coefficient in normally distributed samples and Spearman’s correlation in non-normally distributed samples. For all correlations, the Bonferroni correction was applied and an adjusted *p value (p value <0.05/n; n = 5) <0.01 was considered significant while two-sided tests of hypotheses were used throughout.

Results
All demographic data of our study are outlined in Table 1. There were no differences in age, body mass index, blood pressure values, or relevant dialysis-specific parameters. Detailed information on primary renal disease, prescribed antihypertensive, antidiabetic, and HD-related medication is listed in online supplementary Table 2. Figure 1a shows representative 23Na-MR images obtained before HD treatment of a HD-

| Table 1. Clinical characteristics of HD-CVD and HD-control patients |
|---------------------------------------------------------------|
| Demographics                                                 | HD-control | HD-CVD | p value |
| Individuals, n                                               | 29         | 23     |         |
| Women’s quota, %                                             | 31         | 26     |         |
| Age, years                                                   | 62.8±8.8   | 65.3±7.2 | 0.28   |
| BMI, kg/m²                                                   | 28.1±4.9   | 28.8±4.0 | 0.60   |
| Diabetes mellitus, n                                         | 5          | 6      |         |
| Hypertension, n                                              | 29         | 23     |         |
| BP medication                                                | 3.0±1.5    | 3.0±1.4 | 0.92   |
| SBP, mm Hg                                                   | 140±23     | 132±17 | 0.17   |
| DBP, mm Hg                                                   | 75±11      | 69±12  | 0.09   |
| HD-related parameter                                         |            |        |         |
| HD vintage, years                                            | 1.6 (IQR 3.4) | 2.5 (IQR 4.8) | 0.22  |
| HD technique                                                 | 24 BHD/5 HDF | 20 BHD/3 HDF |         |
| Treatment time, h                                            | 4.5 (IQR 0.75) | 4.75 (IQR 0.75) | 0.39  |
| Residual diuresis, mL/d                                      | 500 (IQR 950) | 300 (IQR 500) | 0.30  |
| IDWG, kg                                                     | 1.8±1.1    | 1.8±1.5 | 0.94   |
| Ultrafiltration, L                                           | 2.2±1.1    | 2.3±1.2 | 0.71   |
| Dialysate Na⁺, mmol/L                                        | 138 (IQR 3) | 138 (IQR 0) | 0.39  |
| Dialysate bicarbonate, mmol/L                                | 32 (IQR 3) | 32 (IQR 3) | 0.95  |
| Laboratory data                                              |            |        |         |
| Plasma Na⁺, mmol/L                                           | 138±2      | 139±3  | 0.19   |
| Plasma K⁺, mmol/L                                            | 5.6±0.9    | 5.6±0.8 | 0.95   |
| hs-CRP, mg/L                                                 | 3.1 (IQR 3.4) | 3.8 (IQR 6.6) | 0.51  |
| VEGF-C, pg/ml                                                | 3,720±900 | 3,170±1,380 | 0.13  |
| BIS data                                                     |            |        |         |
| Total body water, L                                          | 38.2±5.9   | 40.6±7.7 | 0.25  |
| ECW, L                                                       | 18.7±3.2   | 20.0±3.4 | 0.18  |
| ICW, L                                                       | 19.5±3.2   | 20.6±4.6 | 0.37  |
| Ratio ECW/ICW                                                | 0.96±0.12  | 0.99±0.11 | 0.43  |

Variables are presented as mean ± SD or as median and interquartile range (IQR). BMI, body mass index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; IDWG, Interdialytic Weight Gain; BHD, bicarbonate hemodialysis; HDF, hemodiafiltration; hs-CRP, high-sensitive C-reactive protein; VEGF-C, vascular endothelial growth factor-C; ECW, extracellular water; ICW, intracellular water.
CVD patient (right panel) and an age- and gender-matched HD-control patient (left panel), indicating a higher Na\(^+\) signal intensity in the HD-CVD patient. Means of all \(^{23}\text{Na}-\text{MRI}\) scans conducted prior to HD treatment, as shown in Figure 1b and c, revealed that HD-CVD patients presented with significantly higher Na\(^+\) contents in skin (21.7 ± 7.3 vs. 30.2 ± 9.8 a.u., \(p < 0.01\)), as well as in muscle tissue (21.5 ± 3.6 vs. 24.7 ± 6.0 a.u., \(p < 0.05\)). The obtained fluid status detected by BIS did not render a significant difference in excess extracellular volume (OH) 1.8 ± 1.7 versus 2.2 ± 1.7 L, \(p = 0.44\), as shown in Figure 1d. In Figure 2 laboratory results of both groups reveal no difference in plasma concentrations of NT-proBNP (HD-control: 3,410 [IQR 16,360] vs. HD-CVD: 6,860 [IQR 25,690] pg/mL, \(p = 0.24\), Fig. 2a); whereas hs-TnI levels were higher in the HD-CVD group (8.8 [IQR 5.6] vs. 12.4 [IQR 11.9] pg/mL, \(p < 0.01\), Fig. 2b). The observed Na\(^+\) accumulation in HD-CVD patients was accompanied by elevated plasma concentrations of the inflammatory cytokine IL-6 in the HD-CVD group (5.1 [IQR 5.8] vs. 8.5 [IQR 7.9] pg/mL, \(p < 0.05\), Fig. 2c), while high-sensitive CRP did not show a significant difference (Table 1).

Table 2 presents correlations of tissue Na\(^+\) content with HD-related parameters as well as laboratory values of our HD cohort (combined in A and group specific in B/C). Besides the known age-dependency, we found correlations between tissue Na\(^+\) content and OH in all sub-
Fig. 2. Cardiovascular and inflammatory parameters. a No difference in NT-proBNP plasma levels between both groups (logarithmic scale, HD-CVD patients \( n = 23 \), HD-controls \( n = 24 \)). b Elevated hs-TnI plasma levels in HD-CVD patients \( n = 23 \) compared to HD-controls \( n = 24 \). c Higher IL-6 plasma concentrations in HD-CVD patients \( n = 23 \) compared to HD-controls \( n = 24 \). * \( p < 0.05 \).

Table 2. Correlation analysis between skin and muscle sodium content with age, HD-related and laboratory parameter, combined HD cohort (A), HD-controls (B) and HD-CVD patients (C)

| Parameters                  | Muscle Na\(^+\) \( r (95\% \ CI) \) | \( p \) value | Skin Na\(^+\) \( r (95\% \ CI) \) | \( p \) value |
|-----------------------------|-------------------------------------|--------------|---------------------------------|--------------|
| A. Combined HD cohort (CVD + controls) |                                     |              |                                 |              |
| Age                         | 0.312 (0.043; 0.539)                | 0.024        | 0.504 (0.268; 0.683)             | **0.000**    |
| OH                          | 0.585 (0.358; 0.747)                | **0.000**    | 0.403 (0.131; 0.619)             | **0.005**    |
| HD vintage                  | 0.047\(^a\) (−0.229; 0.316)        | 0.740        | 0.139\(^a\) (−0.139; 0.397)      | 0.327        |
| NT-proBNP                   | 0.257\(^a\) (−0.033; 0.507)        | 0.081        | 0.285\(^a\) (−0.002; 0.529)      | 0.052        |
| IL-6                        | 0.222\(^a\) (−0.070; 0.479)        | 0.133        | 0.448\(^a\) (0.185; 0.651)       | **0.002**    |
| B. HD-control group         |                                     |              |                                 |              |
| Age                         | 0.473 (0.129; 0.716)                | 0.010        | 0.556 (0.238; 0.766)             | **0.002**    |
| OH                          | 0.501 (0.132; 0.748)                | 0.011        | 0.379 (−0.019; 0.673)            | 0.062        |
| HD vintage                  | −0.126\(^a\) (−0.471; 0.252)       | 0.516        | −0.098\(^a\) (−0.448; 0.279)     | 0.613        |
| NT-proBNP                   | 0.487\(^a\) (0.104; 0.744)         | 0.016        | 0.316\(^a\) (−0.100; 0.638)      | 0.133        |
| IL-6                        | 0.156\(^a\) (−0.264; 0.526)        | 0.468        | 0.419\(^a\) (0.019; 0.704)       | 0.041        |
| C. HD-CVD group             |                                     |              |                                 |              |
| Age                         | 0.137 (−0.292; 0.520)               | 0.533        | 0.451 (0.048; 0.728)             | 0.031        |
| OH                          | 0.661 (0.332; 0.847)                | **0.001**    | 0.420 (−0.002; 0.715)            | 0.052        |
| HD vintage                  | 0.208\(^a\) (−0.223; 0.571)        | 0.341        | 0.323\(^a\) (−0.103; 0.649)      | 0.132        |
| NT-proBNP                   | 0.002\(^a\) (−0.411; 0.414)        | 0.993        | 0.244\(^a\) (−0.187; 0.596)      | 0.261        |
| IL-6                        | 0.220\(^a\) (−0.211; 0.580)        | 0.312        | 0.449\(^a\) (0.045; 0.727)       | 0.032        |

Pearson’s correlation was used to compute the correlation coefficient (\( r \)) in normally distributed samples. \(^a\) Spearman’s correlation was used to compute the correlation coefficient (\( q \)) in non-normally distributed samples. Bold \( p \) values: considered significance adjusted for Bonferroni correction (* \( p < 0.01 \)); OH, overhydration.
analyses, while IL-6 correlated only with skin Na⁺ content. In contrast, HD-vintage time showed no correlation with tissue Na⁺.

To determine the effect of HD treatment on tissue Na⁺ mobilization, we conducted ²³Na-MRI scans following a regular dialysis procedure. Post-HD scans revealed that – although dialysis was able to remove some of the Na⁺ load – the surplus remained amongst HD-CVD patients, as shown in Figure 3. The difference in Na⁺ content continued to be significant in skin tissue (17.1 ± 5.6 vs. 25.0 ± 8.2 a.u., p < 0.001, Fig. 3a), while in muscle tissue data suggested a trend towards Na⁺ accumulation (16.3 ± 3.2 vs. 18.7 ± 5.7 a.u., p = 0.06, Fig. 3b). Mobilized tissue Na⁺ amount (∆Na⁺) was not different between both groups (Fig. 3c, d).

**Discussion**

Based on recent findings concerning tissue Na⁺ accumulation, fluid overload, and blood pressure regulation, we intended to explore the potential link between tissue Na⁺ deposition and CVD in dialysis patients [25, 26]. This seems to be particularly relevant as in patients with moderately impaired renal function tissue Na⁺ content is closely correlated to left ventricular hypertrophy, a surrogate parameter of CVD [23]. We focused in our study on elderly HD patients as they are tissue Na⁺ overloaded [15] – and seriously affected by a high risk for CVD [27]. We were able to demonstrate that HD patients with a history of cardiovascular events reveal a pronounced tissue Na⁺ accumulation compared to age-matched HD patients without CVD. Clinical data and HD-related parameter did not differ between groups (Table 1). In particular, HD-vintage time was not different between HD-control and HD-CVD patients, nor was there any correlation between HD-vintage time and tissue Na⁺ content (Table 2). This is especially relevant as longtime HD treatment may lead to an increased CVD risk [28]. Long-term fluid overload is known to be associated with CVD development in dialysis patients [29]. Excess extracellular water (OH) as an indicator for edema could play a causal role in the explanation of increased tissue Na⁺ signals [30]. To explore this hypothesis, we complimentary assessed the fluid status of our patients via BIS technique. In studies on dialysis patients, BIS has been
widely utilized to determine fluid status. Increased cardiovascular mortality was thereby associated with even moderate fluid overload [31, 32]. In our study, either HD group presented with a distinct fluid overload (Table 1; Fig. 2d), which correlated to tissue Na⁺ content (Table 2). This correlation is in line with previous observations of tissue Na⁺ and BIS in dialysis patients [33, 34]. However, in our study, none of the BIS-determined parameters were different between both groups. As the extent of fluid overload did not reflect the CVD risk in our cohort of HD patients, ²³Na-MRI detected tissue Na⁺ accumulation could turn out to be a more sensitive marker for CVD in HD patients than extracellular fluid assessment using BIS.

To determine the effect of impaired cardiac function on tissue Na⁺ deposition we measured the NT-proBNP in both groups. NT-proBNP is released by cardiomyocytes upon ventricular stretch and plays an important role as diagnostic marker for congestive heart failure [35, 36]. Natriuretic BNP is almost always increased in HD patients and has been shown to be of diagnostic value for systolic dysfunction in dialysis patients [37]. However, residual renal function and dialysis modality are important confounders for its interpretation making it difficult to define cutoff values [38]. In our study, no significant difference in NT-proBNP could be detected between HD-CVD and HD-control patients, indicating that Na⁺ retention due to heart failure does not explain the observed tissue Na⁺ overload in HD-CVD patients.

Recent investigations shed light on a salt-related regulation of the immune system. Increased Na⁺ thereby resulted in an exacerbation of autoimmune disease whereas in infectious disease clearance of pathogens was facilitated by higher Na⁺ concentrations [39–42]. In HD patients, a close link between subclinical inflammation and predialysis fluid overload is present [43]. Besides water overload, Na⁺ might be also relevant for micro-inflammation in patients with CKD [33]. To assess if inflammation is present in our HD-CVD cohort and whether it is associated with Na⁺ accumulation, plasma concentrations of the pro-inflammatory cytokine IL-6 were determined. We found higher levels of IL-6 in HD patients with a CVD history that correlated with skin Na⁺ amount. Whether tissue Na⁺ plays a direct role in the development of chronic inflammation or even CVD in dialysis patients remains unclear and has to be assessed by basic research and prospective interventional trails. We additionally plan a longitudinal study to follow-up our cohort in future.

Our data suggest that HD is able to mobilize tissue Na⁺ independently of CVD history. The amount of tissue Na⁺ removed by a single HD procedure (ΔNa⁺) did not differ between both groups, resulting in a sustained condition of tissue Na⁺ overload in HD-CVD patients post-HD (Fig. 3). Therefore, nephrologists should consider additional aspects of Na⁺ balance in these patients like dietary salt restriction or adaption of dialysate Na⁺ concentration. In future, ²³Na-MRI could serve as a noninvasive diagnostic tool in the assessment of individualized dialysis regimes in HD-CVD patients.

We are aware of general limitations of our study. Besides the observational approach, our cohort of HD patients presented with several comorbidities, which might explain outliers in both groups. As the prevalence of asymptomatic coronary artery disease in HD patients is relatively high, we cannot exclude occult forms of CVD in our HD-control group [44]. However, the level of plasma hs-TnI as a marker for cardiac damage was significantly higher in the HD-CVD group, indicating a higher prevalence of coronary artery disease in our CVD cohort [45]. Additionally, solely Caucasians were investigated in our study. Results should therefore not be generalized to all ethnicities, which is important as for instance African Americans are known to accumulate higher amounts of tissue Na⁺ [22].

In summary, we present evidence that HD-CVD patients present with elevated tissue Na⁺ content, which cannot be mobilized completely by a single HD procedure. In our study, this overload is independent of HD-vintage time, not paralleled by changes in OH or markers for heart failure, but associated with subclinical inflammation detected by IL-6 elevation. Based on these data, we cannot distinguish between “chicken or egg”: Is tissue Na⁺ overload involved in the development of CVD or does CVD itself lead to tissue Na⁺ retention? Prospective long-term cohort studies have to reveal whether CVD is causal for Na⁺ deposition or vice versa and further continuvative basic research is required to identify underlying mechanisms.

Acknowledgments

We sincerely thank our study participants and the staff of our dialysis core unit. We also thank the Imaging Science Institute (Erlangen, Germany) for providing us with measurement time at the 3T MRI-scanner and for technical support. The present work was performed in (partial) fulfillment of the requirements for obtaining the degree “Dr. med.”
Statement of Ethics

The local Ethics Committee of the University of Erlangen-Nürnberg, Germany approved the study (No. 3948 and 271_17B), which was conducted according to the declaration of Helsinki principles. All participants provided written informed consent.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

This work was supported by Grants from the Deutsche Forschungsgemeinschaft (DFG 5088/1-1) to C.K. and the Else Kröner-Fresenius Foundation (2016_A45) to A.D.

Author Contributions

A.D. and C.K. conceived and designed the study. P.L. implemented, conducted, and analyzed the MRI measurements. A.-C.F., S.H., and D.R. enrolled the participants, conducted the BCM measurements, conceived and carried out laboratory tests, and collected the data. A.D. and C.K. analyzed and interpreted the data. A.-C.F. drafted the manuscript, A.D. and C.K. contributed to the writing of the manuscript. M.U., A.M.N., and M.S. contributed to the study design and critically revised the manuscript. All authors approved the final version of the manuscript.

Data Availability Statement

Full data set is provided on request by Anke Dahlmann (anke.dahlmann@uk-erlangen.de).

References

1 Strazzullo P, D’Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;339:b4567.
2 Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanilly SK, et al. Long-term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334(7599):885.
3 Taylor RS, Ashton KE, Moxham T, Hooper L, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens. 2011 Aug; 24(8):843–53.
4 O’Donnell MJ, Yusuf S, Mente A, Gao P, Mann JF, Teo K, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011 Nov 23; 306(20):2229–38.
5 Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA. 2016 May 24–31;315(20):2200–10.
6 Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor C-dependent buffering mechanism. Nat Med. 2009 May;15(5):545–52.
7 Machnik A, Dahlmann A, Kopp C, Goss J, Wagner H, van Rooijen N, et al. Mononuclear phagocyte system depletion blocks interstitial toxicity-responsiveness enhancer binding protein/vascular endothelial growth factor C expression and induces salt-sensitive hypertension in rats. Hypertension. 2010 Mar;55(3):755–61.
8 Wiig H, Schroder A, Neuhofer W, Jantsch J, Kopp C, Karlsen TV, et al. Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest. 2013 Jul; 123(7):2803–15.
9 Charra B. Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int. 2007 Jan;11(1):21–31.
10 Lee SW. Sodium balance in maintenance hemodialysis. Electrolyte Blood Press. 2012 Dec; 10(1):1–6.
11 Titze J, Mailliet A, Lang R, Gunga HC, Johannes B, Gauquelin-Koch G, et al. Long-term sodium balance in humans in a terrestrial trial space station simulation study. Am J Kidney Dis. 2002 Sep;40(3):508–16.
12 Titze J, Dahlmann A, Lerchl K, Kopp C, Rakova N, Schroder A, et al. Spooky sodium balance. Kidney Int. 2014 Apr;85(4):759–67.
13 Kopp C, Linz P, Wachsmuth L, Dahlmann A, Horbach T, Schoff C, et al. Na magnetic resonance imaging of tissue sodium. Hypertension. 2012 Jan;59(1):167–72.
14 Kopp C, Linz P, Dahlmann A, Hammon M, Jantsch J, Muller DN, et al. (23)Na magnetic resonance imaging-determined tissue sodium in healthy subjects and hypertensive patients. Hypertension. 2010 Mar;55(3):755–61.
15 Dahlmann A, Dorfeld K, Eicher F, Linz P, Kopp C, Mossinger I, et al. Magnetic resonance-determined sodium removal from tissue stores in hemodialysis patients. Kidney Int. 2015 Feb;87(2):434–41.
16 Hammon M, Grossmann S, Linz P, Kopp C, Dahlmann A, Garlisch C, et al. (23)Na magnetic resonance imaging of the lower leg of acute heart failure patients during diuretic treatment. PLoS One. 2015;10(10):e0141336.
17 Hammon M, Grossmann S, Linz P, Seuss H, Hammon R, Rosenhauer D, et al. 3 Tesla (23) Na magnetic resonance imaging during acute kidney injury. Acad Radiol. 2017 Sep;24(9):1086–93.
18 Kopp C, Beyer C, Linz P, Dahlmann A, Hammon M, Jantsch J, et al. Na+ deposition in the fibrotic skin of systemic sclerosis patients detected by 23Na magnetic resonance imaging. Rheumatology. 2017 Apr 1;56(4):674.
19 Deger SM, Wang P, Fissell R, Ellis CD, Book er C, Sha F, et al. Tissue sodium accumulation and peripheral insulin sensitivity in maintenance hemodialysis patients. J Cachexia Sarcopenia Muscle. 2017 Jun;8(3):500–7.
20 Kopp C, Linz P, Maier C, Wabel P, Hammon M, Nagel AM, et al. Elevated tissue sodium deposition in patients with type 2 diabetes on hemodialysis detected by (23)Na magnetic resonance imaging. Kidney Int. 2018 May;93(5):1191–7.
21 Qirjazi E, Salemo FR, Akbari A, Hur L, Penny J, Scholl T, et al. Tissue sodium concentrations in chronic kidney disease and dialysis patients by lower leg sodium-23 magnetic resonance imaging. Nephrol Dial Transplant. 2020 Apr 6. Epub ahead of print.
22 Sahinoz M, Tintara S, Deger SM, Alsouqi A, Crescenzi RL, Mambungo C, et al. Tissue sodium stores in peritoneal dialysis and hemodialysis patients determined by 23-sodium magnetic resonance imaging. Nephrol Dial Transplant. 2020 Dec 22;36(7):1307–17.
23 Schneider MP, Raf U, Kopp C, Scheppach JB, Toncar S, Wanner C, et al. Skin sodium concentration correlates with left ventricular hypertrophy in CKD. J Am Soc Nephrol. 2017 Jun;28(6):1867–76.
24 Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017: a report from the American Heart Association. Circulation. 2017 Mar 7;135(10):e146–603.

25 Canaud B, Kooman J, Selby NM, Taal M, Francis S, Kopperschmidt P, et al. Sodium and water handling during hemodialysis: new pathophysiologic insights and management approaches for improving outcomes in end-stage kidney disease. Kidney Int. 2019 Feb;95(2):296–309.

26 Pinter J, Chazot C, Stuard S, Moissl U, Canaud B, Sodium, volume and pressure control in haemodialysis patients for improved cardiovascular outcomes. Nephrol Dial Transplant. 2020 Mar 1;35(Suppl 2):ii23–30.

27 Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018 Oct 1;33(Suppl_3):iii28–34.

28 Sumida K, Yamagata K, Iseki K, Tsubakihara Y. Different impact of hemodialysis vintage on cause-specific mortality in long-term hemodialysis patients. Nephrol Dial Transplant. 2016 Feb;31(2):298–305.

29 Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van Wyck D, Bunnapradist S, Horwich TB, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation. 2009 Feb 10;119(5):671–9.

30 Rossitto G, Mary S, Chen JY, Boder P, Chew KS, Neves KB, et al. Tissue sodium excess is not hypertonic and reflects extracellular volume expansion. Nat Commun. 2020 Aug 24;11(1):4222.

31 Wilzemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C, et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant. 2009 May;24(5):1574–9.

32 Zoccali C, Moissl U, Chazot C, Mallamaci F, Tripepi G, Arkosy O, et al. Chronic fluid overload and mortality in ESRD. J Am Soc Nephrol. 2017 Aug;28(8):2491–7.

33 Mitsidis N, Alshehi FMS, Mc Hough D, Shalamanova L, Wilkinson F, Alderdice J, et al. Salt and water retention is associated with micro-inflammation and endothelial injury in chronic kidney disease. Nephron. 2019 Nov;143(4):234–42.

34 Mitsidis N, McHugh D, Swiecicka A, Mitra R, Brenchley P, Parker GJM, et al. Extracellular resistance is sensitive to tissue sodium status; implications for bioimpedance-derived fluid volume parameters in chronic kidney disease. J Nephrol. 2020 Feb;33(1):119–27.

35 Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998 Jul 30;339(5):321–8.

36 Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, et al. Lasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol. 2003 Nov 19;42(10):1793–800.

37 Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 2001 Apr;59(4):1559–66.

38 Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008 Sep;19(9):1643–52.

39 Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic T(H)17 cells. Nature. 2013 Apr 25;496(7446):518–22.

40 Jantsch J, Schatz V, Friedrich D, Schroder A, Kopp C, Siegert I, et al. Cutaneous Na+ storage strengthens the antimicrobial barrier function of the skin and boosts macrophage-driven host defense. Cell Metab. 2015 Mar 3;21(3):493–501.

41 Neubert P, Weichselbaum A, Reitinger G, Schatz V, Schroder A, Ferdinand JR, et al. HiF1A and NFAT5 coordinate Na+-boosted antibacterial defense via enhanced autophagy and autolysosomal targeting. Autophagy. 2019 Nov 2;15(11):1899–916.

42 Jobin K, Müller DN, Jantsch J, Kurts C. Sodium and its manifold impact on our immune system. Trends Immunol. 2021 Jun;42(6):469–79.

43 Dekker MJE, Marcelli D, Canaud BJ, Carioni P, Wang YD, Grassmann A, et al. Impact of fluid status and inflammation and their interaction on survival: a study in an international hemodialysis patient cohort. Kidney Int. 2017 May;91(5):1214–23.

44 De Vriese AS, Vandecasteele SJ, Van den Bergh B, De Geeter FW. Should we screen for coronary artery disease in asymptomatic chronic dialysis patients? Kidney Int. 2012 Jan;81(2):143–51.

45 deFilippi C, Wasserman S, Rosanio S, Tibbler E, Spenger H, Tocchi M, et al. Cardiac tropinin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003 Jul 16;290(3):353–9.